Why the study?
The relationship between rapid lymphangioma growth, inflammation, and vessel invasion remains unclear, and the role of the MIB-1 labeling index in fast-growing versus non-proliferating lymphangioma needed evaluation.
Is the MIB-1 labeling index higher in fast-growing lymphangiomas compared to non-proliferating lymphangiomas?
Is the MIB-1 labeling index higher in fast-growing lymphangiomas compared to non-proliferating lymphangiomas?
The MIB-1 labeling index may serve as an important marker for assessing the proliferative potential of lymphangiomas.
MIB-1 index may inform proliferation risk in lymphangioma management; leaves open its utility for treatment selection or outcomes.
Our concept for the treatment of lymphangioma is simple resection if it is small and adjacent to the surface of the skin and intralesional injection of OK- 32 if it is big. Resection of the mass is performed if its size has reduced after observation, but persisted. The rapid growth of the lymphangioma has been considered to be due to inflammation and invasion of the vessels, but their relationship remains unclear. Our hypothesis is that the Mib1-labeling index of endothelial cells of fast-growing lymphangioma is larger than that of non-proliferating lymphangioma. Mib-1 labeling index shows their ability of proliferation. In our study, we could show the high potential cells of lymphangioma had high MIB1 index using the immunological technique of the pathology.
No takes yet. Share an insight, caveat, or question.
Kishi et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: